CAS9 Technology Market Estimated to Perceive Distinctive Growth by 2022 :

Pune, India, September, 2018 /press release/- Market Research Future Published a Half-Cooked Research Report on CAS9 Technology Market Research Report.

CAS9 or CRISPR-Cas9 is a gene-editing technology that enables scientists to cut and paste snippets of genetic information in strands of DNA. The technology has huge potential for application in the biotech industry and is already making a huge difference across many scientific fields such as agriculture and healthcare.

In pharmaceuticals it is used in developing new drugs and in agriculture, it is expanding research and development activities aimed at evaluating seed yield, oil content yield, and drought tolerance traits deployed in key agricultural crops and etc. Many research projects are going on deploying novel yield, oil content and drought tolerance traits using CAS 9 technology in plants such as Camelina, canola, soybean, rice and other agriculturally significant crops to increase yields.

The CAS9 technology also helps the healthcare industry to treat patients with fatal diseases. The promising results delivered by this technology is a key driving factor acting as tailwind escalating the market growth.  Also, substantial investments put into R&D activities are encouraging the market growth on the global platform.

Acknowledging the accruals, the market is enjoying currently, demonstrating the potential to grow further in the years to come, Market Research Future (MRFR) in its recently published study report asserts that the global CAS9 technology market will be valued exponentially by 2022, registering a striking CAGR during the forecast period (2016 – 2022). 

Factors such as augmented adoption of CAS9 in precision medicine along with the increasing applications such as edit RNA and shorter snippets of DNA in small organisms, like bacteria, and etc. drive the market growth. Projects such as the human genome and the growing adoption of genetics for livestock and agriculture research are fostering the market growth. Improving economic conditions enabling access to the quality of life and improved healthcare supports the market growth.

However, as the CAS9 Technology is still in its nascent stage, there are some challenges to the growth of the market. Factors such as insufficient funds for R&D high cost of development and maintenance, along with the data safety concerns, and ethical considerations among others inhibit the market growth. Nevertheless, private and public funding programs are rapidly increasing the funds for R&D.

The year 2018 has been phenomenal for the CAS9 patents. Many patents filed since 2011 have been cleared this year.

Access Report @

CAS9 Technology Market - Segments

The MRFR analysis is segmented into five key dynamics for enhanced understanding.

By Medium : Enzyme, and RNA, among others

By Application       : DNA sequencing, DNA repair, Gene Library Development, Cell Line Engineering, Genetic Engineering, Cancer, and Hepatitis B Gene Therapy among others.

By Delivery : IV Infusion, Injection, and Inhalation among others.

By End-user : Hospitals, Cardiac Care Centers, Ambulatory and others. 

By Region                :  Europe, North America, APAC, and the Rest-of-the-World (RoW).

The subsegment Genetic engineering holds the largest market share by applications.

CAS9 Technology Market - Regional Analysis

Globally, the North American region dominates the CAS9 technology market with the largest market share. The presence of the global players is a key driving force acting as a tailwind to the market growth.  Simultaneously, factors such as the encouraging research and development activities transpired in healthcare along with the increased uptake of advanced technologies and high healthcare expenditures are substantiating the market growth. Owing to the rising demands for CAS9 Technology procedures, the CAS9 technology market in North America is projected to create a larger revenue pocket by 2022. The US, backed by the increasing demand for DNA Sequencing, accounts for the major contributor to the market growth.

Whereas Europe accounts for the second-largest market for CAS9 technology, globally, attributing to the recent technological advancements that took place in the field and the augmenting uptake of the technology in the region. 

Additionally, the presence of large medical facilities and rising per capita health care expenditures in the region support the market growth. Besides, factors such as government support and funding from the public & private sectors for research & development are estimated to accelerate the market growth in the region over the forecasted period.

The Asia Pacific CAS9 technology market is emerging as one of the lucrative markets, growing rapidly. Backed by the rising demand for DNA sequencing and the increasing adoption of the technology in the procedures, APAC market is expected to register a phenomenal CAGR during the forecast period. The market is expected to perceive huge contributions from some of the APAC countries such as South Korea, Japan, India, and China.

Global CAS9 Technology Market - Competitive Landscape

The rapidly growing market for CAS9 technology is fiercely competitive and fragmented with many well-established as well as small & new entrants forming the competitive edge. Innovation, new technology launch and Brand reinforcement remain the popular trends for the key players in the market. The growth statistics of the Nerve market presage the probable heights the market can reach further.

Key Players:

Fervent players leading the global CAS9 technology market include CRISPR Therapeutics, Thermo Fisher Scientific Inc., Lonza, Agilent Technologies, GenScript, Editas Medicine, Horizon Discovery Group plc., New England Biolabs, Albany Molecular Research Inc., Transposagen, Inc., and CRISPR Therapeutics.

Industry/Innovations/Related News:

September 18, 2018 – Thermo Fisher Scientific Inc. (US), a leading biotechnology product development company announced licensing intellectual property surrounding CRISPR technologies from the Broad Institute and ERS Genomics. The company already holds licenses to other genome editing technologies such as CRISPR-Cas9 and others.  These licenses expand Thermo Fisher’s industry-leading genome editing capabilities.